In prostate cancer, m6A modification level was upregulated, and the expression levels of METTL3 (Chen et al., 2021b), METTL14 (Barros-Silva et al., 2020), VIRMA (Barros-Silva et al., 2020), RNA binding motif protein 15 (RBM15), HNRNPC, HNRNPA2B1, YTHDC2, YTHDF1 (Liu et al., 2022c) and YTHDF2 (Li et al., 2020) increased. The gene discussed is METTL3; the disease is prostate cancer.